Vontobel Holding Ltd. Tg Therapeutics, Inc. Transaction History

Vontobel Holding Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	BUY	$17.21 - $25.28 $163,495 - $240,160	9,500 New	9,500 $222,000
Q1 2023 Jun 03, 2024	BUY	$10.23 - $19.34 $122,760 - $232,080	12,000 New	12,000 $180,000
Q1 2023 Apr 12, 2023	SELL	$10.23 - $19.34 $100,254 - $189,532	-9,800 Reduced 44.95%	12,000 $180,000
Q4 2022 Feb 14, 2023	BUY	$5.01 - $11.83 $109,218 - $257,894	21,800 New	21,800 $257,000
Q3 2021 Oct 29, 2021	BUY	$21.78 - $40.45 $17,424 - $32,360	800 Added 13.81%	6,594 $219,000
Q1 2021 May 11, 2021	SELL	$41.61 - $54.3 $163,818 - $213,779	-3,937 Reduced 40.46%	5,794 $279,000
Q4 2020 Feb 12, 2021	BUY	$25.27 - $54.9 $245,902 - $534,231	9,731 New	9,731 $510,000

347

88M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.85B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

Stay updated on Vontobel Holding Ltd. with notifications on news.